ERBB2 and breast carcinoma: ASAT was paired with luminal B/HER2-negative-like breast cancer, triple-negative or basal-like breast cancer, endometrial cancer, liver cancer, luminal B-like breast cancer, ovarian cancer, esophageal adenocarcinoma, endometrioid ovarian cancer, and endometrioid endometrial cancer.